Scott Bell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1749768/publications.pdf

Version: 2024-02-01

254 papers	16,996 citations	22153 59 h-index	17105 122 g-index
273 all docs	273 docs citations	273 times ranked	15616 citing authors

#	Article	IF	Citations
1	Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, e35-e43.	0.7	8
2	Emerging Nonpulmonary Complications for Adults With Cystic Fibrosis. Chest, 2022, 161, 1211-1224.	0.8	2
3	Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 487-489.	5.6	2
4	Neutrophil respiratory burst activity is not exaggerated in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 707-712.	0.7	2
5	A Systematic Literature Review of Indoor Air Disinfection Techniques for Airborne Bacterial Respiratory Pathogens. International Journal of Environmental Research and Public Health, 2022, 19, 1197.	2.6	12
6	Genomic diversity and antimicrobial resistance of Prevotella species isolated from chronic lung disease airways. Microbial Genomics, 2022, 8, .	2.0	6
7	CD161 expression defines new human Î³Î´ T cell subsets. Immunity and Ageing, 2022, 19, 11.	4.2	3
8	Express Yourself: Quantitative Real-Time PCR Assays for Rapid Chromosomal Antimicrobial Resistance Detection in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2022, 66, e0020422.	3.2	4
9	Redesign of the Australian Cystic Fibrosis Data Registry: A multidisciplinary collaboration. Paediatric Respiratory Reviews, 2021, 37, 37-43.	1.8	3
10	Antimicrobial resistance: Concerns of healthcare providers and people with CF. Journal of Cystic Fibrosis, 2021, 20, 407-412.	0.7	13
11	Rapid macrolide and amikacin resistance testing for Mycobacterium abscessus in people with cystic fibrosis. Journal of Medical Microbiology, 2021, 70, .	1.8	4
12	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. Clinical Pharmacokinetics, 2021, 60, 1081-1102.	3.5	4
13	Lesch-Nyhan disease causes impaired energy metabolism and reduced developmental potential in midbrain dopaminergic cells. Stem Cell Reports, 2021, 16, 1749-1762.	4.8	11
14	We are not doing enough to prevent the spread of COVIDâ€19 and other respiratory viruses in Australian hospitals. Medical Journal of Australia, 2021, 215, 152.	1.7	4
15	Anti-LPS IgA and IgG Can Inhibit Serum Killing of Pseudomonas aeruginosa in Patients with Cystic Fibrosis. Infection and Immunity, 2021, 89, e0041221.	2.2	5
16	Prevention of SARS-CoV-2 (COVID-19) transmission in residential aged care using ultraviolet light (PETRA): a two-arm crossover randomised controlled trial protocol. BMC Infectious Diseases, 2021, 21, 967.	2.9	3
17	Dissemination of Mycobacterium abscessus via global transmission networks. Nature Microbiology, 2021, 6, 1279-1288.	13.3	47
18	Outcomes of artery embolisation for cystic fibrosis patients with haemoptysis: a 20â€year experience at a major Australian tertiary centre. Internal Medicine Journal, 2021, 51, 1526-1529.	0.8	0

#	Article	IF	Citations
19	The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124.	10.7	573
20	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
21	Sexual and reproductive health in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2020, 26, 685-695.	2.6	7
22	Seven P's of publication practices. Journal of Cystic Fibrosis, 2020, 19, 333-335.	0.7	3
23	Cystic fibrosis â€“ Ten promising therapeutic approaches in the current era of care. Expert Opinion on Investigational Drugs, 2020, 29, 1107-1124.	4.1	8
24	Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry. Scientific Reports, 2020, 10, 17421.	3.3	26
25	A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 355-358.	0.7	113
26	Influence of climate variables on the rising incidence of nontuberculous mycobacterial (NTM) infections in Queensland, Australia 2001â€“2016. Science of the Total Environment, 2020, 740, 139796.	8.0	31
27	Benchmarking service provision, scope of practice, and skill mix for physiotherapists in adult cystic fibrosis care delivery. Physiotherapy Theory and Practice, 2020, , 1-7.	1.3	1
28	Pursuit of Equity. Journal of Cystic Fibrosis, 2020, 19, 171.	0.7	0
29	Stimulation of L-type calcium channels increases tyrosine hydroxylase and dopamine in ventral midbrain cells induced from somatic cells. Stem Cells Translational Medicine, 2020, 9, 697-712.	3.3	17
30	Pathogen to commensal? Longitudinal within-host population dynamics, evolution, and adaptation during a chronic >16-year Burkholderia pseudomallei infection. PLoS Pathogens, 2020, 16, e1008298.	4.7	12
31	The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Frontiers in Immunology, 2020, 11, 303.	4.8	219
32	Finding the relevance of antimicrobial stewardship for cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 511-520.	0.7	18
33	Centralised versus outreach models of cystic fibrosis care should be tailored to the needs of the individual patient. Internal Medicine Journal, 2020, 50, 232-235.	0.8	0
34	Current infection control practices used in Australian and New Zealand cystic fibrosis centers. BMC Pulmonary Medicine, 2020, 20, 16.	2.0	5
35	Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals. Critical Care Medicine, 2020, 48, 623-633.	0.9	188
36	Duplex real-time PCR assay for the simultaneous detection of Achromobacter xylosoxidans and Achromobacter spp.. Microbial Genomics, 2020, 6, .	2.0	3

#	Article	IF	Citations
37	Differentiating Population Spatial Behavior Using Representative Features of Geospatial Mobility (ReFGeM). ACM Transactions on Spatial Algorithms and Systems, 2020, 6, 1-25.	1.4	3
38	Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study. BMC Pulmonary Medicine, 2019, 19, 146.	2.0	15
39	Indoor hospital air and the impact of ventilation on bioaerosols: a systematic review. Journal of Hospital Infection, 2019, 103, 175-184.	2.9	109
40	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 2019, 18, 236-243.	0.7	84
41	Nonâ€invasive ventilation versus oxygen therapy in cystic fibrosis: A 12â€month randomized trial. Respirology, 2019, 24, 1191-1197.	2.3	15
42	A non-randomised single centre cohort study, comparing standard and modified bowel preparations, in adults with cystic fibrosis requiring colonoscopy. BMC Gastroenterology, 2019, 19, 89.	2.0	8
43	Mutations in ACTL6B Cause Neurodevelopmental Deficits and Epilepsy and Lead to Loss of Dendrites in Human Neurons. American Journal of Human Genetics, 2019, 104, 815-834.	6.2	59
44	CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. Journal of Cystic Fibrosis, 2019, 18, 700-707.	0.7	38
45	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	5.8	62
46	Transmission of bacteria in bronchiectasis and chronic obstructive pulmonary disease: Low burden of cough aerosols. Respirology, 2019, 24, 980-987.	2.3	6
47	Infection risks for patients from healthcare workers with cystic fibrosis â€•Reply. Respirology, 2019, 24, 393-394.	2.3	0
48	Abolition of Pseudomonas aeruginosa AUSTâ€01 from an Australian CF center: Do other strains remain?. Pediatric Pulmonology, 2019, 54, 515-516.	2.0	0
49	JCF â€“ progress in 2018. Journal of Cystic Fibrosis, 2019, 18, 1-5.	0.7	0
50	Reply: More on Causal Inference Studies. Annals of the American Thoracic Society, 2019, 16, 646-646.	3.2	0
51	Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2019, 25, 636-645.	2.6	5
52	Disruption in research publishing â€“ the open access revolution. Journal of Cystic Fibrosis, 2019, 18, 747-749.	0.7	4
53	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic Society, 2019, 16, 22-28.	3.2	458
54	Differential expression of genes and receptors in monocytes from patients with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 342-348.	0.7	17

#	Article	IF	Citations
55	Multiâ€centre ethics and research governance review can impede nonâ€interventional clinical research. Internal Medicine Journal, 2019, 49, 722-728.	0.8	11
56	Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. Gene, 2019, 683, 12-17.	2.2	6
57	Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta) Tj ETQq1 1 0.784314 rgBT /Overl 271-277.	0.7	18
58	Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei. Thorax, 2019, 74, 87-90.	5.6	23
59	Genomic and phenotypic comparison of environmental and patient-derived isolates of Pseudomonas aeruginosa suggest that antimicrobial resistance is rare within the environment. Journal of Medical Microbiology, 2019, 68, 1591-1595.	1.8	16
60	Quantitative real-time PCR assay for the rapid identification of the intrinsically multidrug-resistant bacterial pathogen Stenotrophomonas maltophilia. Microbial Genomics, 2019, 5, .	2.0	8
61	Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) into an Effective Model of Forebrain Neural Progenitor Cells and Mature Neurons. Bio-protocol, 2019, 9, e3188.	0.4	22
62	ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis, 2018, 17, 153-178.	0.7	521
63	Biomarkers: Their Role in CFTR Modulator Therapies from Early Development to the Clinic. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1375-1376.	5.6	3
64	The experience of men and women with cystic fibrosis who have become a parent: A qualitative study. Journal of Clinical Nursing, 2018, 27, 1702-1712.	3.0	8
65	Bronchiectasis: Yet another systemic disease?. Respirology, 2018, 23, 797-798.	2.3	0
66	Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of Pseudomonas aeruginosa in People with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 348-355.	5.6	48
67	Work environment risks for health care workers with cystic fibrosis. Respirology, 2018, 23, 1190-1197.	2.3	7
68	Defining antimicrobial resistance in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 696-704.	0.7	66
69	Reply to Zuckerman and Saiman: Use of Masks in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1589-1590.	5.6	1
70	Antimicrobial resistance in cystic fibrosis: Does it matter?. Journal of Cystic Fibrosis, 2018, 17, 687-689.	0.7	18
71	Whole genome sequencing reveals the emergence of a Pseudomonas aeruginosa shared strain sub-lineage among patients treated within a single cystic fibrosis centre. BMC Genomics, 2018, 19, 644.	2.8	16
72	Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21

#	Article	IF	Citations
73	Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention. Respirology, 2018, 23, 1006-1022.	2.3	24
74	Inhaled corticosteroids for bronchiectasis. The Cochrane Library, 2018, 5, CD000996.	2.8	17
75	Disruption of GRIN2B Impairs Differentiation in Human Neurons. Stem Cell Reports, 2018, 11, 183-196.	4.8	53
76	Anomalies in T Cell Function Are Associated With Individuals at Risk of Mycobacterium abscessus Complex Infection. Frontiers in Immunology, 2018, 9, 1319.	4.8	18
77	Face Masks Reduce the Release of Pseudomonas aeruginosa Cough Aerosols When Worn for Clinically Relevant Periods. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1339-1342.	5.6	34
78	Lower airway microbiota for â€˜biomarkerâ€™ measurements of cystic fibrosis disease progression?. Thorax, 2018, 73, 1001-1003.	5.6	5
79	Optimism, opportunities, outcomes: the Australian Cystic Fibrosis Data Registry. Internal Medicine Journal, 2018, 48, 721-723.	0.8	7
80	Transcriptomic analysis of longitudinal Burkholderia pseudomallei infecting the cystic fibrosis lung. Microbial Genomics, 2018, 4, .	2.0	30
81	Cover Image, Volume 173A, Number 2, February 2017. American Journal of Medical Genetics, Part A, 2017, 173, i.	1.2	0
82	A Rapid Pipeline to Model Rare Neurodevelopmental Disorders with Simultaneous CRISPR/Cas9 Gene Editing. Stem Cells Translational Medicine, 2017, 6, 886-896.	3.3	19
83	Clostridium difficileinfection in cystic fibrosis: an uncommon but life-threatening complication. Respirology Case Reports, 2017, 5, e00204.	0.6	10
84	Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?. Thorax, 2017, 72, 297-299.	5.6	7
85	Within-Host Evolution of Burkholderia pseudomallei during Chronic Infection of Seven Australasian Cystic Fibrosis Patients. MBio, 2017, 8, .	4.1	70
86	Tropical Australia is a potential reservoir of non-tuberculous mycobacteria in cystic fibrosis. European Respiratory Journal, 2017, 49, 1700046.	6.7	11
87	CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 475-482.	0.7	57
88	Effect of Nerve Stimulation Use on the Success Rate of Ultrasound-Guided Subsartorial Saphenous Nerve Block. Regional Anesthesia and Pain Medicine, 2017, 42, 25-31.	2.3	11
89	The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. Presse Medicale, 2017, 46, e139-e164.	1.9	12
90	JCF â€“ 2016. Journal of Cystic Fibrosis, 2017, 16, 6.	0.7	0

#	Article	IF	Citations
91	Sources and dynamics of fluorescent particles in hospitals. Indoor Air, 2017, 27, 988-1000.	4.3	30
92	Early Intervention of Cystic Fibrosis Pulmonary Exacerbations Based on Home Monitoring. eICE through the Looking Glass. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1090-1092.	5.6	1
93	Implication of LRRC4C and DPP6 in neurodevelopmental disorders. American Journal of Medical Genetics, Part A, 2017, 173, 395-406.	1.2	40
94	The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. Journal of Cystic Fibrosis, 2017, 16, 70-77.	0.7	34
95	Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey. Journal of Cystic Fibrosis, 2017, 16, 85-88.	0.7	21
96	Learningâ€™s from the Editors Desk â€“ 2017. Journal of Cystic Fibrosis, 2017, 16, 645-646.	0.7	0
97	Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis. PLoS ONE, 2017, 12, e0172179.	2.5	31
98	Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis. BMC Pulmonary Medicine, 2017, 17, 138.	2.0	11
99	Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508delâ€CFTR. Annals of the American Thoracic Society, 2017, 14, 213-219.	3.2	78
100	A Novel Method and Its Application to Measuring Pathogen Decay in Bioaerosols from Patients with Respiratory Disease. PLoS ONE, 2016, 11, e0158763.	2.5	20
101	High ambient temperature and risk of intestinal obstruction in cystic fibrosis. Journal of Paediatrics and Child Health, 2016, 52, 430-435.	0.8	18
102	A de novo frameshift mutation in chromodomain helicase DNAâ€binding domain 8 (CHD8): A case report and literature review. American Journal of Medical Genetics, Part A, 2016, 170, 1225-1235.	1.2	36
103	Lesch-Nyhan Syndrome: Models, Theories, and Therapies. Molecular Syndromology, 2016, 7, 302-311.	0.8	52
104	JCF-2015. Journal of Cystic Fibrosis, 2016, 15, 1.	0.7	5
105	<scp>P</scp>seudomonas aeruginosa antibiotic resistance in <scp>A</scp>ustralian cystic fibrosis centres. Respirology, 2016, 21, 329-337.	2.3	43
106	The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry. Annals of the American Thoracic Society, 2016, 13, 1014-1015.	3.2	5
107	Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study. Lancet Respiratory Medicine,the, 2016, 4, 636-645.	10.7	19
108	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354, 751-757.	12.6	462

#	Article	IF	Citations
109	The role of anaerobic bacteria in the cystic fibrosis airway. Current Opinion in Pulmonary Medicine, 2016, 22, 637-643.	2.6	37
110	Methicillin-resistant Staphylococcus aureus acquisition in healthcare workers with cystic fibrosis: a retrospective cross-sectional study. BMC Pulmonary Medicine, 2016, 16, 78.	2.0	8
111	The effect of CFTR modulation on the disease progression of cystic fibrosis in the era of precision medicine. Journal of Cystic Fibrosis, 2016, 15, e20.	0.7	1
112	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2016, 15, 495-502.	0.7	59
113	Infection in cystic fibrosis: impact of the environment and climate. Expert Review of Respiratory Medicine, 2016, 10, 505-519.	2.5	24
114	Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. European Respiratory Journal, 2016, 47, 420-428.	6.7	102
115	An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis. BMC Pulmonary Medicine, 2015, 15, 116.	2.0	23
116	Idiosyncratic reactions are the most common cause of abnormal liver function tests in patients with cystic fibrosis. Internal Medicine Journal, 2015, 45, 395-401.	0.8	9
117	Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Medical Journal of Australia, 2015, 202, 21-23.	1.7	133
118	Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium. Frontiers in Microbiology, 2015, 6, 1036.	3.5	144
119	Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis. PLoS ONE, 2015, 10, e0144022.	2.5	17
120	Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
121	Evaluation of phenotypic screening tests for carbapenemase production in Pseudomonas aeruginosa from patients with cystic fibrosis. Journal of Microbiological Methods, 2015, 111, 105-107.	1.6	5
122	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 507-514.	0.7	62
123	Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. Journal of Cystic Fibrosis, 2015, 14, 361-369.	0.7	61
124	Cystic fibrosis. Nature Reviews Disease Primers, 2015, 1, 15010.	30.5	403
125	Inhaled Antibiotics in Cystic Fibrosis (CF) and Non-CF Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 267-286.	2.1	30
126	The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis. Lancet Respiratory Medicine,the, 2015, 3, 640-650.	10.7	26

#	Article	IF	Citations
127	A new phase of CFTR treatment for cystic fibrosis?. Lancet Respiratory Medicine,the, 2015, 3, 662-663.	10.7	3
128	Future trends in cystic fibrosis demography in 34 European countries. European Respiratory Journal, 2015, 46, 133-141.	6.7	238
129	Burkholderia stagnalis sp. nov. and Burkholderia territorii sp. nov., two novel Burkholderia cepacia complex species from environmental and human sources. International Journal of Systematic and Evolutionary Microbiology, 2015, 65, 2265-2271.	1.7	149
130	Molecular surveillance for carbapenemase genes in carbapenem resistant Pseudomonas aeruginosa in Australian patients with cystic fibrosis. Pathology, 2015, 47, 156-160.	0.6	10
131	Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial. Journal of Physiotherapy, 2015, 61, 142-147.	1.7	23
132	Whole-Genome Sequences of Five Burkholderia pseudomallei Isolates from Australian Cystic Fibrosis Patients. Genome Announcements, 2015, 3, .	0.8	10
133	New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. , 2015, 145, 19-34.		140
134	Viability ofPseudomonas aeruginosain cough aerosols generated by persons with cystic fibrosis. Thorax, 2014, 69, 740-745.	5.6	79
135	Practical Guidelines: Lung Transplantation in Patients with Cystic Fibrosis. Pulmonary Medicine, 2014, 2014, 1-22.	1.9	58
136	Pregnancy and cystic fibrosis: Approach to contemporary management. Obstetric Medicine, 2014, 7, 147-155.	1.1	29
137	Elevated metal concentrations in the CF airway correlate with cellular injury and disease severity. Journal of Cystic Fibrosis, 2014, 13, 289-295.	0.7	71
138	JCF â€" 2014 and beyond. Journal of Cystic Fibrosis, 2014, 13, 610-611.	0.7	0
139	Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Review of Anti-Infective Therapy, 2014, 12, 1277-1296.	4.4	27
140	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 527-538.	10.7	372
141	Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. European Respiratory Journal, 2014, 44, 922-930.	6.7	71
142	A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis. BMC Infectious Diseases, 2014, 14, 307.	2.9	20
143	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis, 2014, 13, S23-S42.	0.7	438
144	Molecular Imprint of Exposure to Naturally Occurring Genetic Variants of Human Cytomegalovirus on the T cell Repertoire. Scientific Reports, 2014, 4, 3993.	3.3	19

#	Article	IF	Citations
145	Reduced Mucosal Associated Invariant T-Cells Are Associated with Increased Disease Severity and Pseudomonas aeruginosa Infection in Cystic Fibrosis. PLoS ONE, 2014, 9, e109891.	2.5	58
146	Challenges of providing care to adults with cystic fibrosis. , 2014, , 286-303.		1
147	Geographical Differences in First Acquisition of Pseudomonas aeruginosa in Cystic Fibrosis. Annals of the American Thoracic Society, 2013, 10, 108-114.	3.2	40
148	<scp>ICU</scp> outcomes in cystic fibrosis following invasive ventilation. Respirology, 2013, 18, 585-586.	2.3	2
149	Change in the Executive Editorial Team at JCF. Journal of Cystic Fibrosis, 2013, 12, 545-546.	0.7	0
150	Accurate assessment of systemic iron status in cystic fibrosis will avoid the hazards of inappropriate iron supplementation. Journal of Cystic Fibrosis, 2013, 12, 303-304.	0.7	7
151	Sputum neutrophils in cystic fibrosis patients display a reduced respiratory burst. Journal of Cystic Fibrosis, 2013, 12, 352-362.	0.7	42
152	Management of comorbidities in older patients with cystic fibrosis. Lancet Respiratory Medicine,the, 2013, 1, 164-174.	10.7	83
153	Screening bacterial metabolites for inhibitory effects against Batrachochytrium dendrobatidis using a spectrophotometric assay. Diseases of Aquatic Organisms, 2013, 103, 77-85.	1.0	73
154	High-throughput single-nucleotide polymorphism-based typing of shared Pseudomonas aeruginosa strains in cystic fibrosis patients using the Sequenom iPLEX platform. Journal of Medical Microbiology, 2013, 62, 734-740.	1.8	9
155	Aztreonam for inhalation solution, challenges to drug approval and integration into CF care. Journal of Cystic Fibrosis, 2013, 12, 99-101.	0.7	2
156	Within-Host Evolution of Burkholderia pseudomallei over a Twelve-Year Chronic Carriage Infection. MBio, 2013, 4, .	4.1	121
157	SharedPseudomonas aeruginosagenotypes are common in Australian cystic fibrosis centres. European Respiratory Journal, 2013, 41, 1091-1100.	6.7	59
158	Factors Influencing Acquisition of Burkholderia cepacia Complex Organisms in Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2013, 51, 3975-3980.	3.9	33
159	Ivacaftor in severe cystic fibrosis lung disease and a <scp>G</scp> 551 <scp>D</scp> mutation. Respirology Case Reports, 2013, 1, 52-54.	0.6	8
160	Comparison of the US and Australian Cystic Fibrosis Registries: The Impact of Newborn Screening. Pediatrics, 2012, 129, e348-e355.	2.1	46
161	The risk of airborne influenza transmission in passenger cars. Epidemiology and Infection, 2012, 140, 474-478.	2.1	41
162	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 539-549.	0.7	85

#	Article	IF	Citations
163	Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. Journal of Cystic Fibrosis, 2012, 11, 461-479.	0.7	421
164	Pseudomonas aeruginosa Exhibits Frequent Recombination, but Only a Limited Association between Genotype and Ecological Setting. PLoS ONE, 2012, 7, e44199.	2.5	114
165	Integrative Therapies for People with Cystic Fibrosis. , 2012, , 113-126.		3
166	Room ventilation and the risk of airborne infection transmission in 3Âhealth care settings within a large teaching hospital. American Journal of Infection Control, 2011, 39, 866-872.	2.3	81
167	Cystic fibrosis in Australia, 2009: results from a data registry. Medical Journal of Australia, 2011, 195, 396-400.	1.7	40
168	Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time PCR and high-resolution melting curve analysis. Clinical Microbiology and Infection, 2011, 17, 1403-1408.	6.0	12
169	Transition of adolescents with cystic fibrosis from paediatric to adult care. Clinical Respiratory Journal, 2011, 5, 64-75.	1.6	46
170	Superior vena cava obstruction due to total implantable venous access devices in cystic fibrosis: Case series and review. Respiratory Medicine CME, 2011, 4, 99-104.	0.1	1
171	Clonal complex Pseudomonas aeruginosa in horses. Veterinary Microbiology, 2011, 149, 508-512.	1.9	25
172	Gaming console exercise and cycle or treadmill exercise provide similar cardiovascular demand in adults with cystic fibrosis: a randomised cross-over trial. Journal of Physiotherapy, 2011, 57, 35-40.	1.7	53
173	Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology, 2011, 53, 193-201.	7.3	103
174	Comparison of Three Molecular Techniques for Typing Pseudomonas aeruginosa Isolates in Sputum Samples from Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 263-268.	3.9	78
175	A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation. New England Journal of Medicine, 2011, 365, 1663-1672.	27.0	1,920
176	Anti-inflammatory therapies in bronchiectasis. , 2011, , 223-238.		6
177	Effect of Temperature on Cystic Fibrosis Lung Disease and Infections: A Replicated Cohort Study. PLoS ONE, 2011, 6, e27784.	2.5	87
178	Treatment of pulmonary exacerbations in cystic fibrosis. Therapy: Open Access in Clinical Medicine, 2011, 8, 623-643.	0.2	1
179	The month of July: an early experience with pandemic influenza A (H1N1) in adults with cystic fibrosis. BMC Pulmonary Medicine, 2010, 10, 8.	2.0	17
180	Narrowing of Tâ€cell receptor beta variable repertoire during symptomatic herpesvirus infection in transplant patients. Immunology and Cell Biology, 2010, 88, 125-135.	2.3	15

#	Article	IF	Citations
181	Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation. Medical Journal of Australia, 2010, 193, 356-365.	1.7	120
182	Exercise testing in patients with cystic fibrosis: Why and which?. Journal of Cystic Fibrosis, 2010, 9, 299-301.	0.7	5
183	Identification of an unusual Brucella strain (BO2) from a lung biopsy in a 52 year-old patient with chronic destructive pneumonia. BMC Microbiology, 2010, 10, 23.	3.3	109
184	Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2009, 47, 1503-1509.	3.9	52
185	Randomized Trial of a Decision Aid for Patients with Cystic Fibrosis Considering Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 761-768.	5.6	57
186	Inhaled steroids for bronchiectasis. The Cochrane Library, 2009, , CD000996.	2.8	57
187	Death after Lung Transplantation in Cystic Fibrosis Patients Infected with Burkholderia cepacia. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 257-258.	5.6	18
188	Genetic Modifiers of Liver Disease in Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2009, 302, 1076.	7.4	256
189	Gene expression characteristics of a cystic fibrosis epidemic strain ofPseudomonas aeruginosaduring biofilm and planktonic growth. FEMS Microbiology Letters, 2009, 292, 107-114.	1.8	40
190	Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?. Internal Medicine Journal, 2009, 39, 527-531.	0.8	14
191	Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagnostic Microbiology and Infectious Disease, 2009, 63, 127-131.	1.8	90
192	Sexual and reproductive health in men with cystic fibrosis: Consistent preferences, inconsistent practices. Journal of Cystic Fibrosis, 2009, 8, 264-269.	0.7	18
193	Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax, 2009, 64, 926-931.	5.6	122
194	Sugar sweet and deadly?. Microbiology (United Kingdom), 2009, 155, 665-666.	1.8	2
195	Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand. Research in Microbiology, 2008, 159, 194-199.	2.1	18
196	Neutrophils in cystic fibrosis. Thorax, 2008, 64, 81-88.	5.6	176
197	High prevalence of a class 1 integron-associated aadB gene cassette in Pseudomonas aeruginosa isolates from an Australian cystic fibrosis patient population. Pathology, 2008, 40, 524-525.	0.6	2
198	Symptomatic and Asymptomatic Viral Recrudescence in Solid-Organ Transplant Recipients and Its Relationship with the Antigen-Specific CD8 ⁺ T-Cell Response. Journal of Virology, 2007, 81, 11538-11542.	3.4	40

#	Article	IF	Citations
199	Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal, 2007, 30, 487-495.	6.7	55
200	Phenotypic Characterization of Clonal and Nonclonal Pseudomonas aeruginosa Strains Isolated from Lungs of Adults with Cystic Fibrosis. Journal of Clinical Microbiology, 2007, 45, 1697-1704.	3.9	100
201	Exacerbations in cystic fibrosis: 2 {middle dot} Prevention. Thorax, 2007, 62, 723-732.	5.6	38
202	Pulmonary exacerbations in cystic fibrosis and bronchiectasis. Thorax, 2007, 62, 288-290.	5.6	24
203	Geneâ€“environmental interaction in asthma. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 75-82.	2.3	46
204	Beta-lactam allergy in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2007, 6, 297-303.	0.7	74
205	Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERONï¿½-CMV. Transplant Infectious Disease, 2007, 9, 165-170.	1.7	154
206	A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. British Journal of Clinical Pharmacology, 2007, 63, 438-450.	2.4	45
207	Epidemiological Analysis of Methicillin-ResistantStaphylococcus aureusIsolates From Adult Patients With Cystic Fibrosis. Infection Control and Hospital Epidemiology, 2006, 27, 201-203.	1.8	8
208	Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients. Clinical Pharmacokinetics, 2006, 45, 1099-1114.	3.5	54
209	Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax, 2006, 61, 969-974.	5.6	73
210	Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax, 2006, 61, 146-154.	5.6	75
211	Protease IV production in Pseudomonas aeruginosa from the lungs of adults with cystic fibrosis. Journal of Medical Microbiology, 2006, 55, 1641-1644.	1.8	28
212	Pubertal development and its influences on bone mineral density in Australian children and adolescents with cystic fibrosis. Journal of Paediatrics and Child Health, 2005, 41, 317-322.	0.8	33
213	Clinical presentation of metabolic alkalosis in an adult patient with cystic fibrosis. Respirology, 2005, 10, 254-256.	2.3	7
214	Has the time come to prescribe azithromycin in cystic fibrosis patients?. Internal Medicine Journal, 2005, 35, 73-74.	0.8	1
215	Macrolides in cystic fibrosis. Chronic Respiratory Disease, 2005, 2, 85-98.	2.4	23
216	Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet, The, 2005, 366, 463-471.	13.7	225

#	Article	IF	Citations
217	Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm Conditions. Journal of Clinical Microbiology, 2005, 43, 5085-5090.	3.9	203
218	MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?. Journal of Cystic Fibrosis, 2005, 4, 205-207.	0.7	10
219	Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. European Respiratory Journal, 2004, 24, 101-106.	6.7	113
220	Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax, 2004, 59, 149-155.	5.6	138
221	Vitamin A levels in patients with CF are influenced by the inflammatory response. Journal of Cystic Fibrosis, 2004, 3, 143-149.	0.7	36
222	Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element-based PCR assays. Journal of Medical Microbiology, 2004, 53, 1089-1096.	1.8	102
223	Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. Journal of Hospital Infection, 2004, 56, 208-214.	2.9	66
224	Sub-inhibitory concentrations of ceftazidime and tobramycin reduce the quorum sensing signals of Pseudomonas aeruginosa. Pathology, 2004, 36, 571-575.	0.6	32
225	Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: comparison with healthy controls. Osteoporosis International, 2003, 14, 404-411.	3.1	57
226	Genomovar Diversity Amongst Burkholderia cepacia Complex Isolates From an Australian Adult Cystic Fibrosis Unit. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 434-437.	2.9	18
227	Antibiotic desensitization in adults with cystic fibrosis. Respirology, 2003, 8, 359-364.	2.3	44
228	'Iron lung': Distinctive bronchoscopic features of acute iron tablet aspiration. Respirology, 2003, 8, 541-543.	2.3	25
229	Burkholderia pseudomallei: another emerging pathogen in cystic fibrosis. Thorax, 2003, 58, 1087-1091.	5.6	63
230	Evidence for Spread of a Clonal Strain of Pseudomonas aeruginosa among Cystic Fibrosis Clinics. Journal of Clinical Microbiology, 2003, 41, 2266-2267.	3.9	81
231	Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation, 2003, 75, 1556-1560.	1.0	86
232	Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax, 2002, 57, 212-216.	5.6	459
233	Pamidronate Results in Symptom Control of Hypertrophic Pulmonary Osteoarthropathy in Cystic Fibrosis. Chest, 2002, 121, 1363-1364.	0.8	42
234	Prevalence of Complementary and Alternative Medicine Use by Adults with Cystic Fibrosis. Journal of Pharmacy Practice and Research, 2002, 32, 320-323.	0.8	3

#	Article	IF	Citations
235	Optimising nutrition in cystic fibrosis. Journal of Cystic Fibrosis, 2002, 1, 47-50.	0.7	16
236	Nebulised dornase alpha: adherence in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2002, 1, 255-259.	0.7	37
237	Novel application of biological glue in the management of a complicated pneumothorax in cystic fibrosis. Pediatric Pulmonology, 2002, 34, 138-140.	2.0	6
238	Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Internal Medicine Journal, 2001, 31, 23-26.	0.8	20
239	Energy cost of physical activity in cystic fibrosis. European Journal of Clinical Nutrition, 2001, 55, 690-697.	2.9	32
240	Multidrug resistant tuberculosis. Thorax, 2001, 56, 980-980.	5.6	1
241	Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. European Journal of Clinical Investigation, 2000, 30, 553-559.	3.4	69
242	Asthma care. Thorax, 2000, 55, 535-535.	5.6	2
243	Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10391-10396.	7.1	307
244	Trepopnoea due to positional narrowing of the left main bronchus. Australian and New Zealand Journal of Medicine, 1999, 29, 838-839.	0.5	0
245	Repeatability and methodology of resting energy expenditure in patients with cystic fibrosis. Respiration Physiology, 1999, 115, 301-307.	2.7	10
246	Pulmonary eosinophilia associated with aminoglutethimide. Australian and New Zealand Journal of Medicine, 1998, 28, 670-671.	0.5	2
247	Nutrition in adults with cystic fibrosis. Clinical Nutrition, 1998, 17, 211-215.	5.0	48
248	Nutrition and survival in cystic fibrosis.. Thorax, 1996, 51, 971-972.	5.6	42
249	Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis.. Thorax, 1996, 51, 126-131.	5.6	97
250	Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction.. Thorax, 1996, 51, 159-163.	5.6	16
251	Can tumor necrosis factor-Î± (TNF-Î±) be reliably measured in blood?. Pediatric Pulmonology, 1995, 19, 226-230.	2.0	5
252	To the editor: On tumor necrosis factor Î± in CF. Pediatric Pulmonology, 1994, 17, 411-411.	2.0	4

#	Article	IF	Citations
253	An unusual intrabronchial foreign body in an asthmatic patient. Medical Journal of Australia, 1991, 154, 291-291.	1.7	1
254	Antibiotics in Chronic Obstructive Pulmonary Disease, Bronchiectasis and Cystic Fibrosis. , 0, , 389-413.		2